Profile data is unavailable for this security.
About the company
Financiere de Tubize SA is a Belgium-based holding company. The Company holds minor capital in UCB SA. UCB is a Belgian pharmaceutical and specialty chemical company that specializes in two therapeutic areas: diseases of the central nervous system (CNS) and immunology. UCB, together with its subsidiaries, has research and development facilities in Belgium, Germany, Japan, the United Kingdom and the United States. The Company promotes the development of a sustainable biopharma ecosystem in Belgium and possibly in other geographic areas relevant to UCB.
- Revenue in EUR (TTM)0.00
- Net income in EUR183.85m
- Incorporated1928
- Employees--
- LocationFinanciere de Tubize SAAllee de la Recherche, 60BRUXELLES 1070BelgiumBEL
- Phone+32 476490844
- Websitehttp://www.financiere-tubize.be/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ono Pharmaceutical Co Ltd | 2.96bn | 580.43m | 5.31bn | 3.85k | 8.67 | 1.05 | 7.69 | 1.80 | 201.26 | 201.26 | 1,026.05 | 1,665.85 | 0.4987 | 2.37 | 3.47 | 125,694,000.00 | 9.80 | 11.95 | 11.16 | 13.73 | 75.38 | 74.11 | 19.65 | 23.89 | 2.80 | -- | 0.1702 | 32.25 | 12.41 | 11.73 | 13.53 | 19.95 | -6.79 | 12.20 |
| Siegfried Holding AG | 1.38bn | 137.55m | 5.32bn | 3.80k | 36.83 | 5.20 | 23.15 | 3.87 | 29.87 | 29.87 | 299.09 | 211.39 | 0.7046 | 2.00 | 3.80 | 326,556.30 | 7.06 | 6.51 | 8.64 | 7.98 | 25.87 | 23.24 | 10.03 | 9.06 | 1.40 | 14.34 | 0.3217 | 15.26 | 3.41 | 9.87 | -28.16 | 18.34 | 17.95 | 6.72 |
| Halozyme Therapeutics, Inc. | 898.48m | 372.22m | 5.52bn | 373.00 | 15.14 | 12.86 | 12.28 | 6.15 | 3.02 | 3.02 | 7.30 | 3.56 | 0.4724 | 1.30 | 3.77 | 2,539,826.00 | 19.57 | 18.22 | 20.73 | 21.97 | 82.09 | 79.05 | 41.43 | 39.36 | 9.15 | -- | 0.7687 | 0.00 | 25.62 | 40.43 | 39.31 | -- | 26.82 | -- |
| Corcept Therapeutics Incorporated | 596.13m | 134.50m | 5.57bn | 352.00 | 44.18 | 9.17 | 41.11 | 9.35 | 1.27 | 1.27 | 5.64 | 6.12 | 0.9121 | 1.26 | 13.32 | 1,785,668.00 | 20.58 | 21.17 | 25.10 | 23.85 | 98.44 | 98.52 | 22.56 | 27.23 | 3.64 | -- | 0.00 | 0.00 | 20.04 | 13.93 | 4.66 | 7.08 | -14.15 | -- |
| Beijing Tiantan Biological Products Corp | 684.77m | 166.78m | 5.72bn | 4.86k | 34.30 | 4.11 | -- | 8.35 | 0.6444 | 0.6444 | 2.65 | 5.38 | 0.3471 | 0.8137 | 198.92 | 1,076,946.00 | 11.47 | 11.71 | 16.75 | 16.50 | 54.23 | 49.39 | 33.05 | 27.71 | 3.31 | -- | 0.0046 | 16.67 | 21.57 | 12.06 | 25.99 | 16.85 | 29.67 | 38.97 |
| Financiere de Tubize SA | 0.00 | 183.85m | 5.81bn | -- | 31.62 | 3.08 | 31.62 | -- | 4.13 | 4.13 | 0.00 | 42.45 | 0.00 | -- | -- | -- | 9.64 | 7.04 | 9.85 | 7.24 | -- | -- | -- | 145.70 | -- | -- | 0.0161 | 20.94 | -- | -- | 3.50 | -20.93 | -- | 11.61 |
| Guangzhou Baiyunshan Phrmcl Hldgs Co Ltd | 10.00bn | 448.08m | 5.83bn | 28.05k | 13.79 | 1.30 | -- | 0.5829 | 2.11 | 2.11 | 46.99 | 22.28 | 0.9946 | 6.07 | 4.60 | 2,723,576.00 | 4.71 | 5.90 | 8.93 | 12.40 | 16.55 | 18.70 | 4.74 | 5.56 | 1.15 | -- | 0.317 | 30.02 | 6.68 | 12.32 | 2.25 | 3.34 | 27.75 | 12.05 |
| Orion Oyj | 1.43bn | 331.80m | 6.28bn | 3.82k | 18.92 | 6.78 | 16.06 | 4.40 | 2.36 | 2.36 | 10.16 | 6.58 | 0.9593 | 1.53 | 6.94 | 393,502.20 | 22.25 | 19.47 | 28.25 | 24.16 | 59.89 | 59.38 | 23.19 | 20.71 | 1.41 | 143.69 | 0.2174 | 91.83 | -11.26 | 4.01 | -37.97 | 1.89 | 11.82 | 1.55 |
| Elanco Animal Health Inc | 4.22bn | 194.42m | 6.30bn | 9.30k | 32.89 | 1.02 | 7.60 | 1.49 | 0.4087 | 0.4087 | 8.99 | 13.20 | 0.3224 | 1.21 | 5.09 | 478,924.70 | 1.48 | -3.27 | 1.64 | -3.65 | 54.69 | 54.28 | 4.60 | -11.53 | 1.31 | 0.9883 | 0.4005 | -- | 0.136 | 7.57 | -1,478.21 | -- | 2.74 | -- |
| Abbott India Ltd | 681.93m | 144.42m | 6.50bn | 3.81k | 45.03 | 16.43 | 42.64 | 9.54 | 604.57 | 604.57 | 2,854.72 | 1,657.05 | 1.27 | 5.32 | 15.71 | 15,904,690.00 | 26.82 | 20.92 | 36.97 | 28.59 | 45.09 | 44.20 | 21.18 | 17.26 | 1.71 | 131.36 | 0.0169 | 77.06 | 9.35 | 9.72 | 26.52 | 21.68 | 31.08 | 52.32 |
| Grifols SA | 6.81bn | 151.80m | 6.58bn | 23.74k | 47.30 | 1.27 | 10.06 | 0.9657 | 0.2213 | 0.2213 | 9.79 | 8.23 | 0.3115 | 1.21 | 9.02 | 286,836.40 | 1.00 | 2.39 | 1.34 | 3.05 | 38.51 | 40.26 | 3.21 | 7.54 | 0.8005 | 1.58 | 0.5620 | -- | 8.71 | 8.00 | -71.52 | -36.98 | -0.8127 | -- |
Data as of Nov 21 2024. Currency figures normalised to Financiere de Tubize SA's reporting currency: Euro EUR
1.40%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BNP Paribas Asset Management Europe SASas of 29 Nov 2023 | 97.71k | 0.22% |
| Fidelity Management & Research Co. LLCas of 30 Sep 2024 | 89.40k | 0.20% |
| BlackRock Asset Management Deutschland AGas of 08 Nov 2024 | 61.22k | 0.14% |
| Econopolis Wealth Management NVas of 30 Jun 2024 | 60.00k | 0.14% |
| Capricorn Venture Partners NV (Investment Management)as of 31 Aug 2024 | 59.79k | 0.13% |
| Value Square NVas of 31 Jul 2024 | 56.94k | 0.13% |
| Candriam Belgium SAas of 31 Jul 2024 | 54.75k | 0.12% |
| Sunline Pte Ltd.as of 28 Jun 2024 | 53.83k | 0.12% |
| Investor Asset Management BVas of 08 Nov 2024 | 51.00k | 0.12% |
| BlackRock Advisors (UK) Ltd.as of 08 Nov 2024 | 37.22k | 0.08% |
More ▼
Data from 28 Jun 2024 - 08 Nov 2024Source: FactSet Research Systems Inc.
